Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DECREASE-IPC: De-escalating neoadjuvant chemoimmunotherapy in early triple-negative breast cancer
2025-525040-18-00Phase 2Authorised
- Sponsor
- Institut Paoli-Calmettes
- Start
- Jul 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in triple-negative breast cancer (TNBC), sponsored by Institut Paoli-Calmettes. Primary endpoint: Pathologic complete response rate with MRI/biopsy correlation. Planned start Jul 2026; status: authorised.
02
Drugs
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on 2025-525040-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-525040-18-00.